Indotecan (LMP400) and AM13-55: Two novel indenoisoquinolines show potential for treating visceral leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5264-5270

  Balanã Fouce, Rafael ^a   Prada, Christopher F ^a   Requena, José María ^b   Cushman, Mark ^c   Pommier, Yves ^d   Álvarez Velilla, Raquel ^a   Escudero Martínez, José Miguel ^a   Calvo Álvarez, Estefania ^a   Pérez Pertejo, Yolanda ^a   Reguera, Rosa M ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^c PURDUE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AM 13 55; ANTILEISHMANIAL AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; INDOTECAN; ISOQUINOLINE DERIVATIVE; LMP 400; PAROMOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROTOZOAL ACTIVITY; ARTICLE; DNA CLEAVAGE; DRUG EFFICACY; FEMALE; IN VITRO STUDY; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VISCERAL LEISHMANIASIS;

ANIMALS; FEMALE; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; SPLEEN; TRYPANOCIDAL AGENTS;

EID: 84866315649     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00499-12     Document Type: Article

References (36)

1. Aït-Oudhia K, Gazanion E, Vergnes B, Oury B, Sereno D. 2011. Leishmania antimony resistance: what we know what we can learn from the field. Parasitol. Res. 109:1225-1232.
2. Antony S, et al. 2005. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol. Pharmacol. 67:523-530. (Pubitemid 40216745)
3. Bakshi RP, Shapiro TA. 2003. DNA topoisomerases as targets for antiprotozoal therapy. Mini Rev. Med. Chem. 3:597-608.
4. Bakshi RP, Sang D, Morrell A, Cushman M, Shapiro TA. 2009. Activity of indenoisoquinolines against African trypanosomes. Antimicrob. Agents Chemother. 53:123-128.
5. Balaña-Fouce R, Garcia-Estrada C, Perez-Pertejo Y, Reguera RM. 2008. Gene disruption of the DNA topoisomerase IB small subunit induces a non-viable phenotype in the hemoflagellate Leishmania major. BMC Microbiol. 8:113.
6. Balaña-Fouce R, Redondo CM, Pérez-Pertejo Y, Díaz-González R, Reguera RM. 2006. Targeting atypical trypanosomatid DNA topoisomerase I. Drug Discov. Today 11:733-740. (Pubitemid 44038631)
7. Balaña-Fouce R, Reguera RM, Cubría JC, Ordoñez D. 1998. The pharmacology of leishmaniasis. Gen. Pharmacol. 30:435- 443.
8. Bhattacharya SK, et al. 2007. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis. 196:591-598. (Pubitemid 47206107)
9. Berman J. 2005. Miltefosine to treat leishmaniasis. Expert Opin. Pharmacother. 6:1381-1388. (Pubitemid 41030896)
10. Bodley AL, Shapiro TA. 1995. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania.Proc. Natl. Acad. Sci. U. S. A. 92:3726-3730.
11. Bodley AL, Chakraborty AK, Xie S, Burri C, Shapiro TA. 2003. An unusual type IB topoisomerase from African trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 100:7539-7544. (Pubitemid 36760005)
12. Díaz-González R, Pérez-Pertejo Y, Ordóñez D, Balaña-Fouce R, Reguera RM. 2007. Deletion study of DNA topoisomerase IB from Leishmania donovani:searching for a minimal functional heterodimer. PLoS One 2:e1177. doi:10.1371/journal.pone.0001177.
13. Díaz-González R, Pérez-Pertejo Y, Pommier Y, Balaña-Fouce R, Reguera RM. 2008. Mutational study of the "catalytic tetrad" of DNA topoisomerase IB from the hemoflagellate Leishmania donovani: role of Asp-353 and Asn-221 in camptothecin resistance. Biochem. Pharmacol. 76:608-619.
14. Gangneux JP, Sulahian A, Garin YJ, Derouin F. 1997. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum. J. Antimicrob. Chemother. 40:287-289. (Pubitemid 27394026)
15. Gietz RD, Schiestl RH. 1991. Applications of high efficiency lithium acetate transformation of intact yeast cells using single-stranded nucleic acids as carrier. Yeast 7:253-263.
16. Hotez PJ, et al. 2006. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 3:e102. doi:10.1371/journal.pmed.0030102.
17. Hsiang YH, Hertzberg R, Hecht S, Liu LF. 1985. Camptothecin induces protein-linked DNA break via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-14878. (Pubitemid 16211028)
18. Kimutai A, Ngure K, Kiprotich Tonui W, Muita Gicheru M, Bonareri Nyamwamu L. 2009. Leishmaniasis in Northern and Western Africa: a review. Afr. J. Infect. Dis. 3:14-25.
19. Kiselev E, et al. 2011. 7-Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents. J. Med. Chem. 54:6106-6116.
20. Miró G, Cardoso L, Pennisi MG, Oliva G, Baneth G. 2008. Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part two. Trends Parasitol. 24:371-377.
21. Ossorio V, Travi BL, Rensio AR, Peniche AG, Melby PC. 2011. Identification of small molecule lead compounds for visceral leishmaniasis using novel ex vivo splenic explant model system. Plos Negl. Trop. Dis. 5:e962. doi:10.1371/journal.pntd.0000962.
22. Pommier Y. 2006. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6:789-802. (Pubitemid 44450467)
23. Prada CF, et al. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. J. Antimicrob. Chemother., in press.
24. Proulx ME, Desormeaux A, Marquis JF, Olivier M, Bergeron MG. 2001. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob. Agents Chemother. 45: 2623-2627. (Pubitemid 32801920)
25. Prudhomme M. 2003. Rebeccamycin analogues as anti-cancer agents. Eur. J. Med. Chem. 38:123-140. (Pubitemid 36288468)
26. Ready PD. 2010. Leishmaniasis emergence in Europe. Euro Surveill. 15: 19505.
27. Robinson KA, Beverley SM. 2003. Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania. Mol. Biochem. Parasitol. 128:217-228. (Pubitemid 36549251)
28. Sacks D, Anderson C. 2004. Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol. Rev. 301:225-238. (Pubitemid 39318455)
29. Sacks DL, Perkins PV. 1984. Identification of an infective stage of Leishmaniapromastigotes. Science 223:1417-1419.
30. Schwartz E, Hatz C, Blum J. 2006. New world cutaneous leishmaniasis in travelers. Lancet Infect. Dis. 6:342-349. (Pubitemid 43737272)
31. Shu X, et al. 2009. Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 324:804-807.
32. Teicher AB. 2008. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem. Pharm. 75:1262-1271.
33. Thrash C, Voelkel K, DiNardo S, Sternglanz R. 1984. Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity. J. Biol. Chem. 259:1375-1377. (Pubitemid 14104176)
34. Titus RG, Marchand M, Boon T, Louis JA. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545-555. (Pubitemid 16256170)
35. Villa H, et al. 2003. A novel active DNA topoisomerase I in Leishmaniadonovani. J. Biol. Chem. 278:3521-3526. (Pubitemid 36801074)
36. Zuma AA, Cavalcanti DP, Maia MC, de Souza W, Motta MC. 2011. Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi. Int. J. Antimicrob. Agents. 37:449-456.